Barriers in Access to Idarucizumab in Ischemic Stroke in a Middle-Income Country. [PDF]
Neurohospitalist, 2023 Background and Purpose Current stroke guidelines contraindicate the use of thrombolytics if oral anticoagulants are taken within 48 hours of symptom onset.
Rivillas J +6 more
europepmc +2 more sources
Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report [PDF]
Case Reports in Neurology, 2016 We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day.
Waldemar Kafke +2 more
doaj +2 more sources
Tap chi nghien cuu y hoc, 2023 Non-vitamin K antagonist oral anticoagulants are used more and more popularly because they are more effective than vitamin K antagonists. Dabigatran is the only non–vitamin K antagonist oral anticoagulant with an antidote, idarucizumab, in Vietnam.
Ton Duy +2 more
openalex +3 more sources
Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone [PDF]
Surgical neurology international, 2022 Background: Dabigatran is an anticoagulant (novel oral anticoagulant) that is a direct thrombin inhibitor and only recently has a reversal agent, idarucizumab, been made available (2015). Case Description: An 86-year-old male taking dabigatran for atrial
Syed-Abdullah Uddin +5 more
openalex +2 more sources
Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report [PDF]
Journal of Medical Case Reports, 2017 Background Non-vitamin K antagonist oral anticoagulants, including dabigatran, are currently widely used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Sergio Agosti +4 more
doaj +2 more sources
Use of idarucizumab for emergency surgery in patients taking dabigatran
Атеротромбоз, 2022 This article presents modern possibilities for the provision of emergency surgical care to patients with atrial fibrillation, who administered dabigatran etexilate.
O. M. Nesterova +5 more
doaj +2 more sources
The new way of Dabigatran reversal – Idarucizumab
Journal of Education, Health and Sport, 2019 Since last few years a popularity of new oral anticoagulants significantly raised. There are following main direct oral anticoagulants (DOAC) used in therapy: Dabigatran, Rywaroxaban, Apixaban, Endoxaban.
Erwin Ciechański +3 more
doaj +4 more sources
Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study [PDF]
Journal of Cardiovascular Development and DiseaseHeart transplantation (HT) poses high bleeding risks, especially for patients on anticoagulation. This study evaluates the use of idarucizumab for dabigatran (DBG) reversal compared to vitamin K antagonist (VKA) strategies in HT. A retrospective analysis
Antonio Prieto-Romero +10 more
doaj +2 more sources
Idarucizumab for a traumatic head injury patient taking dabigatran [PDF]
International Journal of Emergency Medicine, 2018 Background Dabigatran is one of the four drugs currently used as a direct oral anticoagulant in Japan. Idarucizumab, which specifically targets dabigatran, was recently approved in Japan.
Shuhei Maruyama +7 more
doaj +2 more sources
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]
Cost Effectiveness and Resource AllocationBackground Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot +5 more
doaj +2 more sources